To evaluate the efficacy and tolerability of imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer.
Department of Gynecologic Oncology, Pathology, and Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. rcoleman@mdanderson.org
